July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Post-vitrectomy ocular hemorrhage among United States adults on oral antithrombotics
Author Affiliations & Notes
  • Ronald A Cantrell
    Genentech, South San Francisco, California, United States
  • Jeffrey Ryuta Willis
    Genentech, South San Francisco, California, United States
  • Susanna S Park
    University of California Davis Eye Center, Sacramento, California, United States
  • Yifeng Chia
    Genentech, South San Francisco, California, United States
  • Mariam Abouhossein
    Genentech, South San Francisco, California, United States
  • Giulio Barteselli
    Genentech, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Ronald Cantrell, Genentech, Inc. (E); Jeffrey Willis, Genentech, Inc. (E); Susanna Park, None; Yifeng Chia, Genentech, Inc. (E); Mariam Abouhossein, Genentech, Inc. (E); Giulio Barteselli, Genentech, Inc. (E)
  • Footnotes
    Support  Yes, Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 883. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ronald A Cantrell, Jeffrey Ryuta Willis, Susanna S Park, Yifeng Chia, Mariam Abouhossein, Giulio Barteselli; Post-vitrectomy ocular hemorrhage among United States adults on oral antithrombotics. Invest. Ophthalmol. Vis. Sci. 2018;59(9):883.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Post-vitrectomy ocular hemorrhage (PVOH) has been linked to use of oral antithrombotics (OAT). However, there are no large-scale commercial claims data to support this association. This retrospective analysis of patient data characterized the impact of OAT subtypes on the incidence of PVOH among adults in the United States.

Methods : Data from MarketScan® Commercial Claims and Medicare Supplemental databases were analyzed to identify patients who underwent vitrectomy between January 1, 2009 and September 30, 2015, with/without prior OAT use. OAT subtypes included warfarin, novel oral anticoagulants (NOACs), and antiplatelets; their use was defined as having ≥1 prescription in the 90 days prior to and including the index (surgery) date. The primary outcome measure was the occurrence of ocular hemorrhage (vitreous, preretinal, retinal, subretinal, retrobulbar, suprachoroidal) within 30 days of the index date. Multivariate regression analysis assessed the association between OAT subtype use and PVOH, adjusting for covariates including surgical indication, diabetes, and hypertension.

Results : This analysis included 73,020 patients aged ≥50 years who underwent vitrectomy in the study period. The incidences of PVOH per 100 cases among patients prescribed (n=7356; 10.1%) vs not prescribed OAT were 8.35 (95% CI 7.71–8.98) vs 4.77 (4.61–4.93), respectively (P < 0.0001). Specifically, the incidences of PVOH per 100 cases across those prescribed warfarin (n=2614; 3.6%), NOACs (n=527; 0.7%), antiplatelets (n=3999; 5.5%), and multiple OAT (n=216; 0.3%) were 8.15 (95% CI 7.10–9.20), 5.31 (3.39–7.23), 8.75 (7.88–9.63), and 10.65 (6.50–14.79), respectively (P = 0.03). Among OAT subtypes, the odds of PVOH were significantly greater in patients prescribed warfarin (adjusted odds ratio 1.27, 95% CI 1.09–1.48; P = 0.0026) or antiplatelets (1.21, 1.07–1.37; P = 0.0025), but not greater in those on NOACs (1.08, 0.72–1.61; P = 0.7149), compared with those not prescribed OAT. Preoperative vitreous hemorrhage, vitrectomies requiring laser, diabetes, and hypertension (all P < 0.001) also were associated with increased odds of PVOH.

Conclusions : A prescription for warfarin and antiplatelets, but not NOACs, was significantly associated with an increased risk of PVOH. Given the potential visual consequences of ocular hemorrhage, these results may provide guidance for the informed consent process in the event of vitrectomy surgery.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.